StockVS

Kenvue Inc. (KVUE) 股票分析

防御性消费

Kenvue Inc.

$17.49

$-0.04 (-0.23%)

最后更新: 2026年5月26日

价格走势

最新新闻

新闻由第三方来源提供。不构成投资建议。

分析

公司概述

Kenvue Inc. operates as a prominent consumer health entity with a global footprint spanning the United States, North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. The company is categorized within the Consumer Defensive sector and specifically functions in the Household & Personal Products industry, which typically implies resilience against economic downturns due to the essential nature of its offerings. Kenvue manages a substantial operational scale, evidenced by a market capitalization of $33.41B, annual revenue of $15.12B, and an employee base of 21780. These financial dimensions and workforce size indicate that Kenvue occupies a significant position in the consumer packaged goods landscape, serving a vast distribution network through its three primary segments: Self Care, Skin Health and Beauty, and Essential Health.

财务健康

The company generated revenue of $15.12B with a net income of $1.47B and EBITDA of $3.24B over the trailing twelve months. The substantial gap between total revenue and net income reveals a cost structure where operating expenses, including cost of goods sold and administrative costs, consume a significant portion of top-line growth before reaching the bottom line. Kenvue maintains free cash flow of $1.81B, which provides the financial flexibility to fund operations, manage working capital needs, and potentially return capital to shareholders or service debt obligations. Profitability is further dissected by three key margins: a gross margin of 58.4%, an operating margin of 17.8%, and a profit margin of 9.7%. The high gross margin suggests strong pricing power or low direct material costs relative to sales, while the operating and profit margins reflect the efficiency of the broader business model in converting revenue into operational and net earnings. Regarding liquidity and leverage, the company holds $1.06B in cash against total debt of $8.67B, resulting in a debt-to-equity ratio of 80.58, which indicates a leveraged balance sheet rather than a conservative one. Additionally, the current ratio stands at 0.96, signaling that current assets fall short of current liabilities, suggesting potential pressure on short-term liquidity management. Finally, return metrics show a return on equity of 14.4% and a return on assets of 6.6%, revealing that the company generates returns significantly above the cost of capital for equity holders but operates with a lower asset turnover efficiency typical of capital-intensive or high-debt structures.

估值评估

Kenvue trades with a trailing P/E ratio of 22.93 and a forward P/E of 14.38. The notable difference between these two metrics implies that the market expects a significant acceleration in earnings trajectory over the coming year, as the forward multiple is substantially lower than the historical average. The price-to-book ratio is recorded at 3.10, indicating that the market values the company at more than three times its book value, reflecting a premium assigned to its brand equity and intangible assets rather than just tangible book capital. Alternative valuation metrics include a price-to-sales ratio of 2.21 and an EV/EBITDA of 12.65, which suggest that the market is willing to pay a moderate premium for sales given the company's profitability and cash generation capabilities relative to its enterprise value. In terms of price momentum, the stock has traded between a 52-week high of $25.17 and a 52-week low of $14.02. Without a specific current share price provided in the data, the valuation range establishes the historical volatility boundaries within which the stock has operated. The stock exhibits a beta of 0.57, meaning its price volatility is significantly lower than the broader market, offering a defensive characteristic that dampens downside risk during market corrections while potentially offering slower appreciation during bull markets.

Growth & Income

Kenvue demonstrates revenue growth of 3.2% year-over-year alongside earnings growth of 11.2% year-over-year. The fact that earnings are growing at a rate more than three times faster than revenue implies that the company is successfully leveraging operational efficiencies, cost controls, or pricing power to improve profitability without relying solely on top-line expansion. As a dividend payer, Kenvue offers a dividend yield of 4.8% with a payout ratio of 108.5%. This payout ratio exceeding 100% indicates that the company is paying out more in dividends than it currently reports in net income, likely utilizing cash reserves or non-cash accounting adjustments, which may present a sustainability challenge if earnings do not catch up to the dividend obligations. The overall growth and income profile presents a scenario of modest top-line expansion supported by robust earnings growth and a high-yield dividend, though the elevated payout ratio requires careful monitoring of future earnings stability to ensure the ability to maintain current dividend levels.

同行比较

Kenvue Inc. (KVUE) 在家庭与个人护理产品行业运营。以下是其与市值最接近的同行的比较:

公司 代码 市值 市盈率
Kenvue Inc. KVUE $33.58B 20.8
The Procter & Gamble Company PG $336.34B 21.1
Unilever PLC UL $123.97B 19.0
Colgate-Palmolive Company CL $71.90B 34.8

家庭与个人护理产品行业平均市盈率为29.9倍。Kenvue Inc.的市盈率为20.8。

本分析由AI生成,仅供参考,不构成投资建议。数据可能存在延迟或不准确。在做出投资决策之前,请务必进行自己的研究并咨询合格的财务顾问。

关于Kenvue Inc.

Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.

公司简介以英文显示。

访问官网 →

关键指标

市值
$33.58B
市盈率
20.82
52周最高
$23.94
52周最低
$14.02
平均成交量
20.88M
Beta系数
0.52
股息率
4.75%

数据由Yahoo Finance通过yfinance提供。每日更新。

公司信息

交易所
NYSE
国家
United States
员工数
21,780